Inari Medical PEERLESS Results Show Superiority Of FlowTriever Compared To Catheter-Directed Thrombolytics For Intermediate-Risk Pulmonary Embolism, Published In 'Circulation'; PEERLESS Met Its Primary Composite Endpoint
Portfolio Pulse from Benzinga Newsdesk
Inari Medical announced positive results from the PEERLESS trial, showing the superiority of its FlowTriever device over catheter-directed thrombolytics for treating intermediate-risk pulmonary embolism. The study met its primary endpoint, indicating better patient outcomes with FlowTriever.
October 29, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inari Medical's FlowTriever device demonstrated superior results in the PEERLESS trial, meeting primary endpoints and showing improved patient outcomes compared to catheter-directed thrombolytics.
The positive results from the PEERLESS trial, showing the superiority of Inari's FlowTriever device, are likely to boost investor confidence and positively impact the stock price. The trial's success in meeting its primary endpoint and demonstrating better patient outcomes is a significant achievement for Inari Medical.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100